` 300009 (Anhui Anke Biotechnology Group Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

300009
vs
Shanghai Composite

Over the past 12 months, has underperformed Shanghai Composite, delivering a return of -15% compared to the Shanghai Composite's 8% growth.

Stocks Performance
300009 vs Shanghai Composite

Loading

Performance Gap
300009 vs Shanghai Composite

Loading
300009
Shanghai Composite
Difference

Performance By Year
300009 vs Shanghai Composite

Loading
300009
Shanghai Composite
Add Stock

Competitors Performance
Anhui Anke Biotechnology Group Co Ltd vs Peers

Shanghai Composite
300009
ABBV
AMGN
GILD
VRTX
Add Stock

Anhui Anke Biotechnology Group Co Ltd
Glance View

Market Cap
14.3B CNY
Industry
Biotechnology

Anhui Anke Biotechnology Group Co., Ltd., nestled in the heart of China's Anhui Province, weaves a story that blends innovation with a commitment to health. Founded in 1986, Anke Biotechnology made its mark early by focusing on the development and manufacturing of biopharmaceutical products. The company's narrative is rooted in its pursuit of cutting-edge technology, specifically in the fields of genetic engineering, fermentation technology, and vaccine production. As China looks to bolster its biopharmaceutical sector, Anke stands out with its robust pipeline of recombinant protein drugs and vaccines that cater to widespread public health needs. By leveraging advanced bioengineering processes, the company aims to encapsulate scientific complexity into tangible, life-saving treatments. At the core of its operations is a diverse business model that spans research, development, production, and commercialization of healthcare products. Through strategic alliances and continuous investment in R&D, Anke Biotechnology sustains a competitive edge by bringing innovative therapies to market. Revenue flows from its flagship products like recombinant human growth hormones and interferons, which address critical healthcare demands not just within China, but internationally as well. Furthermore, the company astutely capitalizes on the rising healthcare needs of an aging population, along with the increasing importance of preventive medicine, reflected in its vaccine offerings. It’s this strategic acumen, blended with scientific prowess, that allows Anhui Anke Biotechnology to thrive in an industry characterized by rapid innovation and evolving challenges.

Intrinsic Value
14.1 CNY
Undervaluation 40%
Intrinsic Value
Price
Back to Top